IP Policy / English Article
How Patents Balance Private Rights and the Public Interest
A public-facing explanation of why patent systems disclose technical knowledge while granting time-limited exclusivity.
The Patent System Is a Bargain with Society
A patent is often misunderstood as a monopoly that only benefits the owner. In reality, the patent system is a bargain. The inventor discloses the technical solution to society. In exchange, society grants a time-limited exclusive right. After the term ends, the disclosed technology belongs to the public domain.
This bargain is why patent documents must be public. A patent is not a secret certificate. It is a technical teaching document that lets others learn from the invention, avoid repeating the same work, and develop further improvements.
The Patent System Is a Bargain with Society: practical detail
For innovators, educators, public readers, and companies explaining IP value, this point should be treated as a working step rather than a slogan. The practical work is to connect the article's idea with explaining the patent bargain through disclosure, limited exclusivity, public-domain return, and follow-on innovation. That is what turns a general insight into a repeatable professional service.
The team should record concrete evidence: published patent documents, term limits, technical disclosure examples, licensing records, design-around cases, and expired-patent public use. Without this evidence layer, the method remains only an opinion. With it, the article becomes useful for client communication, internal decision-making, patent drafting, prosecution strategy, and later portfolio review.
A complete application of this section normally ends with a decision: how to protect real technical contribution without treating patents as empty numbers or permanent private control over public knowledge. Ma Su's examiner background matters here because the decision is not based only on enthusiasm; it is tested against technical contribution, support in the disclosure, likely examination reasoning, and business value.
Why Disclosure Matters
Without patents, companies may keep important technology as trade secrets. Some secrets can disappear when engineers leave or when products change. Public patent disclosure creates a durable technical record. Future researchers can read it, compare it, design around it, improve it, or challenge it.
The public interest is therefore not an afterthought. It is built into the system. The price of exclusivity is disclosure.
Why Disclosure Matters: practical detail
For innovators, educators, public readers, and companies explaining IP value, this point should be treated as a working step rather than a slogan. The practical work is to connect the article's idea with explaining the patent bargain through disclosure, limited exclusivity, public-domain return, and follow-on innovation. That is what turns a general insight into a repeatable professional service.
The team should record concrete evidence: published patent documents, term limits, technical disclosure examples, licensing records, design-around cases, and expired-patent public use. Without this evidence layer, the method remains only an opinion. With it, the article becomes useful for client communication, internal decision-making, patent drafting, prosecution strategy, and later portfolio review.
A complete application of this section normally ends with a decision: how to protect real technical contribution without treating patents as empty numbers or permanent private control over public knowledge. Ma Su's examiner background matters here because the decision is not based only on enthusiasm; it is tested against technical contribution, support in the disclosure, likely examination reasoning, and business value.
Why Exclusive Rights Also Matter
Innovation is costly. It requires trial, failure, equipment, personnel, testing, and market risk. If every successful result can be copied immediately, many innovators will underinvest. Patent rights provide a period in which the innovator can recover cost, negotiate licensing, attract financing, or build a market position.
The system is not designed to reward vague ideas. It rewards technical solutions that are new, inventive, useful, and sufficiently disclosed.
Why Exclusive Rights Also Matter: practical detail
For innovators, educators, public readers, and companies explaining IP value, this point should be treated as a working step rather than a slogan. The practical work is to connect the article's idea with explaining the patent bargain through disclosure, limited exclusivity, public-domain return, and follow-on innovation. That is what turns a general insight into a repeatable professional service.
The team should record concrete evidence: published patent documents, term limits, technical disclosure examples, licensing records, design-around cases, and expired-patent public use. Without this evidence layer, the method remains only an opinion. With it, the article becomes useful for client communication, internal decision-making, patent drafting, prosecution strategy, and later portfolio review.
A complete application of this section normally ends with a decision: how to protect real technical contribution without treating patents as empty numbers or permanent private control over public knowledge. Ma Su's examiner background matters here because the decision is not based only on enthusiasm; it is tested against technical contribution, support in the disclosure, likely examination reasoning, and business value.
A Balanced View for Companies
For companies, the patent system should not be used only as a number game. A good portfolio protects real technical contribution, supports R&D direction, and communicates innovation capability. At the same time, companies must respect the public boundary: once a patent expires, the disclosed technology becomes a shared resource.
Protecting intellectual property is therefore not the opposite of protecting the public interest. When the system works properly, it protects both innovation incentives and the long-term accumulation of human knowledge.
A Balanced View for Companies: practical detail
For innovators, educators, public readers, and companies explaining IP value, this point should be treated as a working step rather than a slogan. The practical work is to connect the article's idea with explaining the patent bargain through disclosure, limited exclusivity, public-domain return, and follow-on innovation. That is what turns a general insight into a repeatable professional service.
The team should record concrete evidence: published patent documents, term limits, technical disclosure examples, licensing records, design-around cases, and expired-patent public use. Without this evidence layer, the method remains only an opinion. With it, the article becomes useful for client communication, internal decision-making, patent drafting, prosecution strategy, and later portfolio review.
A complete application of this section normally ends with a decision: how to protect real technical contribution without treating patents as empty numbers or permanent private control over public knowledge. Ma Su's examiner background matters here because the decision is not based only on enthusiasm; it is tested against technical contribution, support in the disclosure, likely examination reasoning, and business value.
Original Chinese Essay
专利如何均衡公众利益？
一边是天价药，一边是廉价仿制药：印度专利法的“原罪”与“救赎”
一边是每月28万卢比的天价专利药，一边是仅需9000卢比的仿制药，印度用一部充满争议的专利法，在全球制药巨头的铜墙铁壁上撕开了一道裂缝。
2018年，电影《我不是药神》横空出世，引发全民热议。徐峥饰演的主角为了救助白血病病友，冒险从印度代购廉价仿制药“格列宁”，戳中了无数观众内心最柔软的地方。
影片背后，是一个真实的故事：陆勇，一位慢粒白血病患者，因无法承受瑞士诺华公司生产的格列卫（格列卫）每月超过2万元的天价，转而从印度购买药效相当、价格仅需4000元甚至更低的仿制药，并帮助其他病友代购。
这不禁让人追问：为什么印度的仿制药能这么便宜？是什么力量打破了跨国药企的专利垄断？ 答案，藏在印度那部充满争议的专利法中。
一场长达七年的专利战
要理解印度专利法的特殊性，最具代表性的案例莫过于诺华公司与印度政府的世纪诉讼。
格列卫，这个全球第一个问世的肿瘤靶向治疗药物，被誉为“抗癌神药”。它由瑞士制药巨头诺华公司研发，能将慢性粒细胞白血病患者的生存率从不到50%提高到90%左右。在美国、欧洲、中国等40多个国家和地区，诺华都顺利获得了专利保护。
然而，在印度，诺华却碰了硬钉子。
1998年，诺华向印度专利局提交格列卫的专利申请，被驳回。2006年，诺华改而申请改进后的伊马替尼B晶型专利，再次被拒。
诺华一怒之下，将印度政府告上法庭，这场官司一直打到印度最高法院。2013年，印度最高法院作出终审判决：驳回诺华的专利申请。
法院认定，诺华申请的伊马替尼B晶型只是在已有药物基础上的微小修改，未达到印度专利法所要求的“创新”和“独创”标准。
这一判决，让无数印度患者得以继续使用价格仅为原研药几十分之一的仿制药。格列卫在印度的月治疗费用高达4000美元，而印度仿制药仅需73美元。
印度专利法的“特殊性”究竟在哪？
印度之所以能成为“世界药房”，源于其独特的历史选择。
1970年的转折点。1970年，印度颁布了独立后的第一部专利法。这部法律做出了一个关键决定：只对药品的生产工艺授予专利，而不对药品本身（产品专利）授予专利。
这意味着，印度制药企业可以通过反向工程，用不同的生产工艺仿制跨国药企的新药。这为印度本土制药业打开了巨大的发展空间。
圣雄甘地曾说：“我不希望我的房子四面被墙围住，窗户也被堵死。我希望来自世界各地的文化之风在我的房子周围自由地吹拂。但我不能忍受它们中的任何一种把我吹倒。”这种思想深刻影响了印度对待外来技术和专利的态度。
2005年的“保留”。直到2005年，为了履行世界贸易组织《与贸易有关的知识产权协议》的义务，印度才修改专利法，开始对药品本身授予专利。
但印度在修法时留了一手。新专利法第3条(d)款规定：仅发现已知物质的新形式，如果该形式不增强该物质的已知功效，不能被视为发明。
正是这一条款，成了诺华格列卫专利申请的“拦路虎”。印度最高法院认为，诺华未能证明其改进型药品比原有药物疗效显著增强，因此不符合专利授权条件。
强制许可：穷人的救命稻草
如果说拒绝“常青专利”是防御，那么强制许可制度就是印度主动出击的武器。
根据《1970年印度专利法》第84条的规定，在专利授权满3年后，任何人都可以申请强制许可，只要满足以下条件之一：公众无法以合理且负担得起的价格获得该专利发明；该专利发明未在印度境内投入使用；该专利发明未能满足向公众提供充分信息的要求。
2012年，印度专利局首次签发了强制许可。对象是拜耳公司的抗癌药“多吉美”。拜耳这款药每月费用高达28万卢比，而印度本土药企Natco Pharma的仿制药价格仅需9000卢比，降幅接近97%。
印度专利局裁定：拜耳的药品价格过高，普通民众根本买不起，也未在印度充分实施，因此授权Natco生产仿制药，但要向拜耳支付销售额6%的特许权使用费。
这一决定让跨国药企震惊。拜耳公司表示“非常失望”，而公益组织则为之叫好。无国界医生组织的代表说：“当药厂哄抬价格并限制供应，专利局能够并将会终结其垄断势力，以确保病人能获得重要的药物。 ”
利弊交织的“原罪”
印度专利法的“特殊性”，让这个国家成为全球穷人的“药房”。目前，印度出口的仿制药占全球仿制药出口量的20%，销往200多个国家，满足了美国40%、英国25%的药品需求。
但是，硬币总有另一面。
跨国药企的不满与撤退。诺华败诉后，明确表示停止向印度供应格列卫，并发誓不在印度进行任何药物研发活动。美国药品研究与制造商协会警告，这“将会阻碍印度未来的创新发展，阻碍印度医学的进步”。
跨国药企减少了在印度的研发投资，因为他们担心投入巨资研发的新药，在印度得不到有效保护。
创新动力不足的隐忧。强制许可制度带来一个悖论：如果创新成果得不到保护，谁还愿意投入巨资研发新药？
据统计，研发一款新药平均需要耗费数十亿美元、历时10年以上。如果没有专利保护带来的垄断利润，制药企业很难收回这笔巨额投入。从这个角度说，高价药背后，确实有创新的代价。
印度专利局也意识到这一点。在多吉美强制许可之后，印度又收到了针对达沙替尼、沙格列汀等药物的强制许可申请，但这些申请均被驳回，因为申请人未能提供确凿证据。这表明，印度在强制许可问题上并非一味“杀富济贫”，也在努力平衡创新激励和公共健康。
制度背后的社会语境
为什么印度敢于挑战跨国药企的专利霸权？这背后有深厚的社会文化根基。
梵赋生命观。印度传统宗教认为，生命源于最高神梵，万物生命皆为梵所赐，一切生命平等，值得尊重。这种生命观深刻影响了印度人对药品可及性的看法：药品不应成为少数人谋取暴利的工具，而应是拯救生命的公共资源。
《印度宪法》明确规定，国家有责任提高人民的营养水平、生活水平，改善公共卫生。在这一宪法义务指导下，为民众提供便宜药品成为印度专利立法的首要考量。
谁是“药神”？
回到《我不是药神》，影片中有一句台词：“世界上只有一种病，就是穷病。 ”
印度专利法的“特殊性”，某种程度上正是对这种“穷病”的制度性回应。它选择了站在穷人一边，用法律手段打破专利垄断，为患者争取生的希望。
但我们也必须看到，原研药企业的研发投入同样值得尊重。没有这些投入，就不会有新药的诞生，也就没有仿制药可仿。
印度专利法的“原罪”在于对专利权的弱化，它的“救赎”在于对生命权的守护。这种在“产权”与“人命”之间的艰难平衡，正是人类面对疾病时的永恒命题。
或许，真正的“药神”，不是某个神通广大的个体，而是一套能够平衡创新激励和公共利益的制度设计。它能鼓励企业研发新药，又能让患者用得起药。
从这个意义上说，印度专利法的尝试和探索，值得我们深思。 正如一位印度法官在判决中所言：“专利不是仅仅为了专利权人的利益，而是为了促进发明和公共利益。 ”